Results 221 to 230 of about 50,964 (281)

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

JAMA Netw Open
Büttner T, Klümper N, Ellinger J, Ritter M, Krausewitz P.   +4 more
europepmc   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

Quercetin Inhibits AKT Ser473 Phosphorylation and Disrupts AKT-Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Cells. [PDF]

Antioxidants (Basel)
Duprat F, Azócar-Plaza S, Castillo-Cáceres MP, Rivas Y, Sanzana-Rosas J, Pampaloni P, Olivas-Henríquez G, Toledo J, Villa JL, Bertinat R, Jara N, Vallejos-Almirall A, Salas A, González-Chavarría I.   +13 more
europepmc   +1 more source

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer. [PDF]

Br J Cancer
Kondrup K, Iisager L, Salachan PV, Nørgaard M, Lamy P, Eeles R, Hansen TF, Osther PJS, Zedan AH, Borre M, Sørensen KD.   +10 more
europepmc   +1 more source

Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer. [PDF]

EJNMMI Res
Ahmed EE, Andrews JR, Ahmed ME, Haloi R, Rhodes LA, Mahon M, Carter DA, Wei N, Thorpe MP, Johnson GB, Kwon ED, Kendi AT.   +11 more
europepmc   +1 more source

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer. [PDF]

Prostate
Kawai T, Maki K, Taguchi S, Fujii Y, Tanaka T, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H.   +13 more
europepmc   +1 more source

Case Report: [²²⁵Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma. [PDF]

Front Oncol
Musabaev I, Goryaynov S, Yu Kochetova T, Krylov V, Ivanov S.   +4 more
europepmc   +1 more source

Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report. [PDF]

Int Cancer Conf J
Terrano V, Perri E, Cioffo C, Mastroianni G, Palumbo MA, Ciardiello F, Troiani T, Napolitano S.   +7 more
europepmc   +1 more source

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. [PDF]

J Pharmacokinet Pharmacodyn
Wang Y, Hadigol M, Lincha VR, Hoffman J, Azad AA, Agarwal N, Matsubara N, Zohren F, DeAnnuntis L, Wang DD.   +9 more
europepmc   +1 more source

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source